Promising drugs, from The Storm Riders
Check out 200+ promising drugs currently in clinical trials for advanced or metastatic breast cancer. Learn the mechanism for how each drug works and find a drug that could work for you!
2018 FDA Oncology Drug Approvals With Canadian Approvals In the Comments
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that NERLYNX® (neratinib) has been included a…
CAR T Cell Therapy
A type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood.
Approved Health Canada Indications and Clinical Use for Ibrance
• In combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
• In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy. Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist.
When the Patient Is the Loser (American Insurer Article)
A major insurer takes a 20-year, first-line standard treatment off its preferred list in one market. But where will it end?
Memorial Sloan Kettering Cancer Center
Provides a database of herbs, botanicals and supplements